Galena to target Abstral as market leader for cancer pain

Tweet Galena Biopharma (NASDAQ:GALE) plans to make its recently acquired Abstral sublingual tablets the market leader for the treatment of breakthrough cancer pain (BTcP) in the U.S., matching the product’s performance in Europe. “Abstral is the latest and best-in-class drug for this indication,” president and CEO Mark Ahn says in an interview with BioTuesdays.com, noting [...]

Galena to acquire Abstral sublingual tablets in U.S.

Tweet Galena Biopharma (NASDAQ:GALE) has entered into an agreement with Orexo AB of Sweden to acquire Abstral (fentanyl) sublingual tablets for sale and distribution in the U.S. Abstral is a new treatment option for inadequately controlled breakthrough cancer pain (BTcP) in patients who are already receiving, and who are tolerant to, opioid therapy for their [...]

Glickman swinging for the fence again in Isotechnika merger

Tweet Richard Glickman is poised to hit another home run with the proposed merger of his closely-held Aurinia Pharmaceuticals and Isotechnika Pharma (TSX:ISA) to create a global nephrology leader. Dr. Glickman has a decades-long track record of successfully developing and selling pharmaceutical and biopharmaceutical companies. For example, in 2001, he co-founded Aspreva Pharmaceuticals which went [...]

Paladin backs away from Afexa

Tweet Paladin Labs (TSX:PLB) will not take up any shares of Afexa Life Sciences (TSX:FXA) under its hostile takeover offer when the bid expires on Friday. A condition of Paladin’s latest offer was that Afexa not increase a breakup fee with friendly suitor Valeant Pharmaceuticals International (NYSE, TSX:VRX). Last week, the breakup fee was increased [...]

Afexa recommends holders take no action on Paladin offer

Tweet The board of Afexa Life Sciences (TSX:FXA) is recommending that shareholders take no action on an amended takeover offer from Paladin Labs (TSX:PLB) of either 81 cents a share in cash or 0.0217 of a Paladin share for each common share of Afexa. Afexa said the board’s decision reflects an announcement that Valeant Pharmaceuticals [...]

Afexa to oppose lifting poison pill

Tweet Afexa Life Sciences (TSX:FXA) will oppose an application on Friday by Paladin Labs (TSX:PLB) before the Alberta Securities Commission to cease trade Afexa’s shareholder rights plans. Earlier today, Paladin said it would enhance its unsolicited takeover offer for all and any of the outstanding shares of Afexa if two shareholder rights plans are waived [...]

Afexa sees benefits in Valeant takeover

Tweet After attracting a friendly all-cash takeover offer from Valeant Pharmaceuticals International (NYSE:VRX) to trump a hostile bid, Afexa Life Sciences (TSX:FXA) is enthused about the path forward with Valeant. “Through our discussions with Valeant, it became apparent that they are interested in all parts of our business, not only the Canadian COLD-FX business,” Afexa [...]

Labopharm to be acquired by Paladin Labs

Tweet Labopharm (NASDAQ:DDSS; TSX:DDS) has accepted a takeover bid from Paladin Labs (TSX:PLB), which will make an offer for all of the common shares of Labopharm at a price of 28.57 cents a share in cash. The purchase price represents a premium of 57.4% over the volume-weighted average price of Labopharm’s shares of 18.15 cents for the 30 [...]

Paladin bids $50 million for Afexa Life Sciences

Tweet Paladin Labs (TSX:PLB) is making an offer to acquire any and all of the issued shares of Afexa Life Sciences (TSX:FXA) for 55 cents a share cash or a stock swap valued at about $50 million, assuming all shares of Afexa not already owned by Paladin are tendered. On July 15, Paladin said it [...]

Paladin Labs acquires 5.37 million more Afexa shares

Tweet Paladin Labs (TSX:PLB) has raised its interest in Afexa Life Sciences (TSX:FXA) to 15.4 million shares or just under 15%  through market purchases on the Toronto Stock Exchange Friday. The 5,374,500 additional common shares of Afexa were purchased for prices between 36 cents and 55 cents. Paladin said it is considering its options regarding [...]

Next Page »